A. Zampella

A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease

This study identifies 3-oxo-DCA as a microbial bile acid that acts as a GPBAR1 agonist and RORγt inverse agonist, reversing inflammation in IBD.

Bile Acids Serve As Endogenous Antagonists Of The Leukemia Inhibitory Factor (LIF) Receptor in Oncogenesis

The paper shows bile acids, specifically GDCA, inhibit LIFR in gastric cancer, suggesting potential for bile acid-based therapies in LIF-driven oncogenesis.

Next generation sequencing analysis of gastric cancer identifies the leukemia inhibitory factor receptor (LIFR) as a driving factor in gastric cancer progression and as a predictor of poor prognosis

This study identifies LIFR as a key driver in gastric cancer progression and a predictor of poor prognosis through RNA-seq analysis of patient samples.

Discovery of a AhR flavonoid agonist that counter-regulates ACE2 expression in rodent models of inflammation and attenuates ACE2-SARS-CoV2 interaction in vitro

This study identifies pelargonidin, a flavonoid that reduces ACE2 expression and SARS-CoV2 binding in inflamed colons via AhR activation.

Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential

This study identifies histotype-specific molecular signatures in gastric cancer using transcriptomic analysis, finding AQP9, CARD14, and CXCR2 as prognostic markers.

Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region

This study identifies steroidal agents that inhibit SARS-CoV-2 entry by targeting binding pockets on the Spike protein's receptor-binding domain.